Access Anti-Müllerian Hormone (AMH) Assay

Helping fertility patients plan for the family they desire 

We offer a simple test to aid healthcare providers in assessing a woman’s ovarian reserve. The Access AMH immunoassay helps guide the clinical management of women struggling with infertility or planning to become pregnant later in life. Partner with us, the market innovator who developed the first ELISA and launched the first automated AMH assay globally, so you can help fertility patients plan for the family they desire. 

Access AMH advantages over other current AMH immunoassays

  • Increase physician and patient confidence with a recombinant human AMH calibrator that is more stable and accurately mirrors AMH in patient samples for greater immunological recognition of antibodies*
  • Experience a 16 times increase in sensitivity

One test, multiple uses

Diagnostic testing of AMH levels is used in:

  • Fertility assessments. AMH testing has significant advantages over other tests, including increased sensitivity and specificity, and consistency in serum levels throughout the menstrual cycle (see Figure 1)1,2

Figure 1. Mean AMH Values across Menstrual Cycle1

AMH levels can be reliably measured during any day of the menstrual cycle.

  • Reproductive aging evaluations. AMH levels decline earlier than other signs of menopause—such as increasing follicle-stimulating hormone (FSH) levels and irregular menses—and could be used to identify age-related infertility3,4

Access AMH advantages over manual assays

  • Reduce testing costs by 16 percent by using an automated AMH test*
  • Decrease technologist handling time by 80 percent and allow for greater walk-away time through random access capabilities and once-a-month system calibration*
  • Achieve 4 times quicker TAT—40 minutes with an automated assay compared with 170 minutes with ELISA*

Evidence for the Access AMH assay

  • The synthetic Access AMH matrix [simulates analyte-free human serum]…[and] is expected to ensure batch-to-batch consistency and assay performance and minimize detection limitations5
  • The automated assay exhibits high levels of stability and sensitivity and shows correlation with the existing ELISA method and between analyzer platforms6

Discover a full line of reproductive assays to meet your testing needs 

Perform a broad range of reproductive testing services with our comprehensive assay portfolio:


 Reproductive Endocrinology  Reproductive Research 
  • AMH
  • DHEA-S
  • hFSH
  • hLH
  • Progesterone
  • Prolactin
  • Sensitive Estradiol
  • SHBG
  • Testosterone
  • AFP (ONTD)
  • Inhibin A
  • Total BhCG (5th IS)
  • Unconjugated Estriol
  • Inhibin B
  • PAPP-A



Access AMH is exclusively available for Beckman Coulter Access and DxI immunoassay analyzers. Access AMH setup is quick and easy.

Pack Size

50 tests

Sample Volume

20 µL

Sample Type

Serum, plasma

Limit of Blank

≤0.01 ng/mL (≤0.07 pmol/L) 

Limit of Detection

≤0.02 ng/mL (≤0.014 pmol/L) 

20% CV LoQ

≤0.08 ng/mL (≤0.57 pmol/L) 

Data Sheet Access AMH

Partner with Beckman Coulter, the market innovator who developed the first ELISA and launched the first automated AMH assay globally, so you can help fertility patients plan for the family they desire.


Brochure Clinical Utility of Access AMH

Review the latest peer-reviewed analytical and clinical evaluations highlighting the value that Access AMH can bring to your patients.

1"Published Scientific Evidence on the Use of Anti-Müllerian Hormone." Beckman Coulter, Inc., 2014, Accessed 22 Aug. 2017. 
2Groome, N. "The Design Features and Performance of a State-of-the-art Fully-automated Anti-Müllerian Hormone Immunoassay for the Beckman Access Family of Immunoassay Systems." Beckman Coulter, Inc., 14 July 2015, Accessed 22 Aug. 2017. 
3Pearson, K et al. "Assessment of the Access AMH Assay as an Automated, High-performance Replacement for the AMH Generation II Manual ELISA." Reprod Biol Endocrol, vol. 14. 2016 doi: 10.1186/s12958-016-0143-3. 
4Shin, SS et al. "A Prospective Multi-site Evaluation of the Intra-menstrual Cycle Variability of Anti-Müllerian Hormone (AMH) Using an Automated AMH Immunoassay." Poster presented at: AACC 2015, July 26-30, 2015, Atlanta, GA. 
5Toner, JP and Seifer, DB. "Why We May Abandon Basal Follicle-stimulating Hormone Testing: A Sea Change in Determining Ovarian Reserve Using Anti-Müllerian Hormone." Fertil Steril, vol. 99. 2013, pp. 1825-30. 
6Harlow, SD et al. "Executive Summary of the Stages of Reproductive Aging Workshop +10: Addressing the Unfinished Agenda of Staging Reproductive Aging." Menopause, vol. 19. 2012, pp. 387-395. doi: 10.1097/gme.0b013e31824d8f40. 
7Dewailly D et al. "The Physiology and Clinical Utility of Anti-Müllerian Hormone in Women." Hum Reprod Update, vol. 20. 2014, pp. 370-85. doi: 10.1093/humupd/dmt062. 

Data available upon request.
Not available in all geographies. Please contact your local Beckman Coulter representative for more information.